

ASX Announcement

29 November 2018

The Manager
Company Announcements
Australian Securities Exchange
Level 5, 20 Bridge Street
SYDNEY NSW 2000

By Electronic Lodgement


Dear Sirs

Results of 2018 Annual General Meeting

The Board of Recce Pharmaceuticals Ltd (ASX: RCE) (**Company**) is pleased to advise that shareholders of the Company passed all Resolutions (outlined in the table on the following page) in the Notice of Meeting dated 29 October 2018 at the 2018 Annual General Meeting held today at 12:00pm (Sydney time) on a show of hands.

For more information, please contact the undersigned on (+61 2) 8072 1400.

Yours faithfully



Alistair McKeough
Company Secretary

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs. Its patented lead candidate known as RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results. Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.



ASX: RCE

Head Office Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (0)2 8075 4585 **F** +61 (0)2 8075 4584

R&D Centre - Perth Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9253 9800 **F** +61 (8) 9253 9899

Washington Office 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

A summary of the total number of proxy votes is as follows:

Resolution	For	Open	Against	Abstain
1. Adoption of Remuneration Report	1,236,883	213,000	114,341	10,000
2. Re-election of Mr James Graham as Director	36,102,947	223,000	84,341	0
3. Re-election of Dr John Prendergast as Director	36,102,947	223,000	84,341	0
4. ASX Listing Rule 7.1A Approval of Future Issue of Securities	36,058,223	223,000	114,341	14,724
5. Ratification of Prior Issue of Equity Securities	36,078,223	223,000	94,341	14,724
6. Related Party Approval of Issue of Shares to Dr John Prendergast	1,222,159	223,000	114,341	14,724
7. Adoption of Employee Incentive Plan	1,136,883	223,000	114,341	100,000
8. Renewal of Proportional Takeover Provisions	35,992,947	223,000	94,341	100,000

For further information please visit www.recce.com.au or contact:

Investor Relations

James Graham
Executive Director
Recce Pharmaceuticals Ltd
Tel: +61 (02) 8075 4585

Media (Australia)

Andrew Geddes
CityPR
Tel: +61 (02) 9267 4511

Media (International)

Sue Charles/Gemma Harris
Instinctif Partners
Tel: +44 (0)20 7866 7860
E: recce@instinctif.com

